Karen E. Stevens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen E. Stevens has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Catherine E. Adams
Medical Research Service, Department of Veterans Affairs Medical Center, Denver, CO, USA
2 shared publicationsMichael A. Kisley
Department of Psychology, University of Colorado, Colorado Springs, CO, USA
2 shared publicationsCindy Hickel
Department of Psychiatry MS 8344, University of Colorado at Denver and Health Sciences Center, Aurora, USA
1 shared publicationDaniel J. Abrams
Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
1 shared publicationEmily Robbins
Department of Psychiatry, University of Colorado-School of Medicine, Aurora, CO, USA
1 shared publicationJeffrey Danielson
Department of Psychiatry MS 8344, University of Colorado at Denver and Health Sciences Center, Aurora, USA
1 shared publication
Latest Publications
- 27 October 2008
- Published by Elsevier in Brain Research
- Vol. 1237, 84-90
Perinatal choline deficiency produces abnormal sensory inhibition in Sprague–Dawley rats
- 27 October 2008
- Published by Elsevier in Brain Research
- Vol. 1237, 84-90
Perinatal choline deficiency produces abnormal sensory inhibition in Sprague–Dawley rats
- 25 July 2008
- Published by Elsevier in Brain Research
- Vol. 1233, 129-136
Olanzapine improves deficient sensory inhibition in DBA/2 mice
- 25 July 2008
- Published by Elsevier in Brain Research
- Vol. 1233, 129-136
Olanzapine improves deficient sensory inhibition in DBA/2 mice
- 30 April 2008
- Published by Springer Nature in Psychopharmacology
- Vol. 198 (3) , 413-420
Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline
Rationale Schizophrenia patients and certain inbred mouse strains (i.e., DBA/2) show deficient sensory inhibition which has been linked to reduced numbers of hippocampal α7 nicotinic receptors and to underlying polymorphisms in the promoter region for the α7 gene. Increasing maternal dietary choline, a selective α7 agonist, during gestation has been shown to produce long-term changes in adult offspring behavior (i.e., improved learning and memory in rats). Objectives The objective of this study is to improve sensory inhibition in DBA/2 mice through maternal choline supplementation. Materials and methods DBA/2 dams were placed on normal (1.1 g/kg) or supplemented (5 g/kg) choline diet throughout gestation and lactation. Offspring were placed on normal diet at weaning and were assessed for sensory inhibition parameters at adulthood. Evoked EEG responses to identical paired auditory stimuli were compared. At the end of the study, the brains were collected for autoradiographic assessment of hippocampal levels of α-bungarotoxin binding to visualize α7 nicotinic receptors. Results Offspring mice which were choline supplemented during gestation showed significantly improved sensory inhibition compared to mice gestated on the normal choline diet. The improvement was produced by a significant reduction in the response to the second stimulus, demonstrating improved inhibition to that stimulus. There was a concurrent increase in α7 receptor numbers in both the CA1 and dentate gyrus regions of the hippocampus suggesting that this increase may be responsible for the improved inhibition. Conclusions These data show that gestational choline supplementation produces permanent improvement in a deficit associated with schizophrenia and may have implications for human prenatal nutrition.
- 30 April 2008
- Published by Springer Nature in Psychopharmacology
- Vol. 198 (3) , 413-420
Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline
Rationale Schizophrenia patients and certain inbred mouse strains (i.e., DBA/2) show deficient sensory inhibition which has been linked to reduced numbers of hippocampal α7 nicotinic receptors and to underlying polymorphisms in the promoter region for the α7 gene. Increasing maternal dietary choline, a selective α7 agonist, during gestation has been shown to produce long-term changes in adult offspring behavior (i.e., improved learning and memory in rats). Objectives The objective of this study is to improve sensory inhibition in DBA/2 mice through maternal choline supplementation. Materials and methods DBA/2 dams were placed on normal (1.1 g/kg) or supplemented (5 g/kg) choline diet throughout gestation and lactation. Offspring were placed on normal diet at weaning and were assessed for sensory inhibition parameters at adulthood. Evoked EEG responses to identical paired auditory stimuli were compared. At the end of the study, the brains were collected for autoradiographic assessment of hippocampal levels of α-bungarotoxin binding to visualize α7 nicotinic receptors. Results Offspring mice which were choline supplemented during gestation showed significantly improved sensory inhibition compared to mice gestated on the normal choline diet. The improvement was produced by a significant reduction in the response to the second stimulus, demonstrating improved inhibition to that stimulus. There was a concurrent increase in α7 receptor numbers in both the CA1 and dentate gyrus regions of the hippocampus suggesting that this increase may be responsible for the improved inhibition. Conclusions These data show that gestational choline supplementation produces permanent improvement in a deficit associated with schizophrenia and may have implications for human prenatal nutrition.
- Open Access
- 1 March 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 100 (1-3) , 86-96
An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients
- 1 March 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 100 (1-3) , 86-96
Open AccessAn initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients